Australia recommends earlier community-pharmacy access to clozapine, with four-week monitoring in focus. https://www.mattheneus.com/editorial/pbac-clozapine-community-pharmacy-four-week-access-monitoring-2026-10-16 #HTA #Pharma #RegulatoryAffairs

Norway limits lecanemab and donanemab dispensing to hospitals, putting specialist oversight and ARIA risk controls at the centre. #HTA #Pharma #RegulatoryAffairs https://www.mattheneus.com/editorial/norway-lecanemab-donanemab-hospital-dispensing-specialist-aria-controls-2026-10-14

Three-in-one molecular panel cleared. Sensible. Cepheid's rapid tests genuinely useful in respiratory season.

#FDACompliance #RegulatoryAffairs #DesignControl

Australia backs broader second-line access to atomoxetine and guanfacine, with implications for ADHD treatment pathways. #HTA #Pharma #RegulatoryAffairs https://www.mattheneus.com/editorial/pbac-atomoxetine-guanfacine-adhd-second-line-access-prescriber-expansion-2026-10-16

Poland backs Basecal 200 reimbursement for six rare metabolic disorders. https://www.mattheneus.com/editorial/aotmit-basecal-200-protein-free-formula-six-acidurias-reimbursement-consent-2026-10-12 #HTA #HealthEconomics #RegulatoryAffairs

Australia recommends broader subsidy access across 14 low-cost antidepressants—what PBAC’s move means for access and HTA. https://www.mattheneus.com/editorial/pbac-fourteen-antidepressants-subsidy-restriction-relaxation-2026-10-16 #HTA #Pharma #RegulatoryAffairs

A direct survival gain underpins Europe’s positive opinion for Rasonque in metastatic pancreatic cancer. https://www.mattheneus.com/editorial/ema-rasonque-metastatic-pancreatic-adenocarcinoma-chmp-opinion-2026-10-15 #HTA #Pharma #RegulatoryAffairs

No evidence submission, no recommendation: Scotland withholds oral Wegovy for weight management. https://www.mattheneus.com/editorial/smc-oral-wegovy-semaglutide-tablets-weight-management-non-submission-2026-10-12 #HTA #Pharma #RegulatoryAffairs

European HTA harmonisation does not eliminate national evidence needs—strong launch plans must account for both layers. https://www.mattheneus.com/editorial/eu-hta-harmonisation-national-evidence-plans-2026-10-15 #HTA #EvidenceSynthesis #RegulatoryAffairs

Health-data access delays are not just operational friction—they belong in the validity plan. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/iqwig-gedig-health-data-access-validity-plan-2026-10-13

The UK regulator is strengthening antidepressant warnings on suicide risk and persistent sexual dysfunction, sharpening patient safeguards. https://www.mattheneus.com/editorial/mhra-antidepressant-suicide-pssd-patient-information-safeguards-2026-10-15 #HTA #RegulatoryAffairs #Pharma

When the comparator bridge fails, added benefit can remain unproven—even with active-treatment evidence. https://www.mattheneus.com/editorial/g-ba-iqwig-benralizumab-hes-mepolizumab-indirect-comparison-infeasible-2026-10-15 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs

Scotland withheld an acalabrutinib recommendation—not over negative evidence, but because no company submission was made. https://www.mattheneus.com/editorial/smc-acalabrutinib-monotherapy-relapsed-refractory-mcl-non-submission-2026-10-12 #HTA #RegulatoryAffairs #Pharma

Watch the ALCOA+ audit trail gaps survive any cloud QMS migration. The platform changes; the data integrity habits don't move without retraining and validation. #MedicalDeviceQMS #ISO13485 #RegulatoryAffairs #DataIntegrity #ALCOA #AuditReady #

173,281 osseointegration failure reports in five months is a PMS signal, not statistical noise. Implant SMEs should be routing this through and benefit-risk review today.
accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/…

#ISO14971 #RegulatoryAffairs #CAPA

Fiexd supplier audit calendars are compliance theater, risk picks the visit (critical part, past finding, recent change), not whatever month it is.

#RegulatoryAffairs #SupplierQuality #RiskManagement

Scotland’s acoramidis decision shows how a company non-submission can become an access gap for people with ATTR-CM. https://www.mattheneus.com/editorial/smc-acoramidis-beyonttra-attr-cm-non-submission-access-gap-2026-10-12 #HTA #Pharma #RegulatoryAffairs

The MHRA’s 2030 roadmap puts AI-assisted protocol checks and real-world evidence at the centre of regulatory modernization. https://www.mattheneus.com/editorial/mhra-2030-ai-protocol-checker-real-world-evidence-strategy-2026-10-14 #HTA #RWE #RegulatoryAffairs

Case-only evidence and high cost proved insufficient for targeted import funding in Poland. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/aotmit-xuriden-dee50-targeted-import-case-series-cost-rejection-2026-09-30

Multinational clinical-trial advice is becoming a permanent part of Europe’s regulatory pathway. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-act-eu-pre-application-advice-permanent-ctis-2026-10-08